Shield Therapeutics PLC PDMR Exercise of Share Options (2352J)
December 18 2020 - 12:15PM
UK Regulatory
TIDMSTX
RNS Number : 2352J
Shield Therapeutics PLC
18 December 2020
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
PDMR Exercise of Share Options
London, UK, 18 December 2020 : Shield Therapeutics plc (LSE:
STX), a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product
Feraccru(R)/Accrufer(R) (ferric maltol), announces that it issued
and allotted 158,730 new Ordinary Shares of 1.5p each on 18
December 2020 following the exercise of options under the Shield
Therapeutics Retention and Performance Share Plan and The Shield
Therapeutics plc Long-Term Incentive Plan.
Tim Watts, Chief Executive Officer and a PDMR, exercised 100,000
options granted to him on 27 August 2019 at an exercise price of
1.5p each. Mr Watts is retaining the resultant ordinary shares and
now holds 648,700 ordinary shares in Shield representing 0.55% of
the Company's issued share capital.
The 158,730 new Ordinary Shares will be admitted to trading on
Aim in accordance with the block listing that the Company applied
for on 2 March 2020.
Following admission, the Company's issued share capital will
comprise 117,505,765 Ordinary Shares and each Ordinary Share
carries one vote. There are no Ordinary Shares held in treasury and
accordingly, the total number of voting rights is 117,505,765. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
1. Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated
with them ("PCA")
a) Name Tim Watts
---------------------------------------- -----------------------------------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
---------------------------------------- -----------------------------------------------------------------------
b) Initial notification/ Initial Notification
amendment
---------------------------------------- -----------------------------------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------------------------------------
a) Name Shield Therapeutics plc
---------------------------------------- -----------------------------------------------------------------------
b) LEI code 213800G74QWY15FC3W71
---------------------------------------- -----------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument Exercise of share options over Ordinary Shares
Identification code
ISIN: GB00BYV81293
---------------------------------------- -----------------------------------------------------------------------
b) Nature of the transaction Exercise of awards over Ordinary Shares under the Company's Retention
and Performance Share
Plan.
---------------------------------------- -----------------------------------------------------------------------
c) Price(s) and volumes(s) 2020 RPSP Award
Price (GBP) Volume
0.015 100,000
--------
---------------------------------------- -----------------------------------------------------------------------
d) Aggregated information
* Aggregate volume 100,000 shares in total
1.5p each
* Price
---------------------------------------- -----------------------------------------------------------------------
e) Date of the transaction 18 December 2020
---------------------------------------- -----------------------------------------------------------------------
f) Place of the transaction Outside of trading venue
---------------------------------------- -----------------------------------------------------------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Lucy Huntington-Bailey, Company
Secretary and General Counsel +44 (0)19 1511 8500
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused
on commercialising its lead product, Feraccru(R)/Accrufer(R), a
novel, stable, non-salt based oral therapy for adults with iron
deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has
been approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s.
Feraccru is commercialised in the UK and Europe by Norgine B.V. and
the Company is currently in the process of selecting a
commercialisation partner for the US market. Shield also has an
exclusive licence agreement with Beijing Aosaikang Pharmaceutical
Co., Ltd., for the development and commercialisation of
Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUWABRROUUAAA
(END) Dow Jones Newswires
December 18, 2020 12:15 ET (17:15 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024
